AudioEye reports that overlooking web accessibility can cost businesses customers, emphasizing the need to address accessibility for growth and compliance.

The FDA approved imlunestrant for treatment of certain adults with breast cancer who experience disease progression after at least one prior line of endocrine therapy.

This data feed is not available at this time. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.